Anders R.L. Meyer
YOU?
Author Swipe
View article: 442 Cellular inflammatory myofibroblastic tumor with rhabdomyoblastic differentiation: Report of a rare tumor with previously unreported immunohistochemical features
442 Cellular inflammatory myofibroblastic tumor with rhabdomyoblastic differentiation: Report of a rare tumor with previously unreported immunohistochemical features Open
Introduction/Objective Inflammatory myofibroblastic tumor (IMT) is a neoplasm of uncertain etiology that predominantly occurs as an abdominal or pulmonary lesion in children and young adults. Histologic patterns include myxoid, hypercellul…
View article: 282 Florid Reactive Periostitis: A Benign Lesion With Concerning Features
282 Florid Reactive Periostitis: A Benign Lesion With Concerning Features Open
Introduction/Objective Florid reactive periostitis is a reactive lesion most commonly affecting the phalanges of young adults. Despite its non-malignant nature, it may mimic aggressive bone tumors clinically, radiologically, and histologic…
View article: 359 A rare and clinically aggressive infiltrative angiomatoid fibrous histiocytoma presenting in an unusual anatomical site posing diagnostic challenges
359 A rare and clinically aggressive infiltrative angiomatoid fibrous histiocytoma presenting in an unusual anatomical site posing diagnostic challenges Open
Introduction/Objective Angiomatoid fibrous histiocytoma (AFH) is a rare mesenchymal tumor, comprising less than 0.3% of soft tissue neoplasms and primarily affecting children and young adults. Its incidence may be underrecognized due to br…
View article: Majority Voting of Doctors Improves Appropriateness of AI Reliance in Pathology
Majority Voting of Doctors Improves Appropriateness of AI Reliance in Pathology Open
As Artificial Intelligence (AI) making advancements in medical decision-making, there is a growing need to ensure doctors develop appropriate reliance on AI to avoid adverse outcomes. However, existing methods in enabling appropriate AI re…
View article: Comprehensive clinicopathological, molecular, and methylation analysis of mesenchymal tumors with <scp> <i>NTRK</i> </scp> and other kinase gene aberrations
Comprehensive clinicopathological, molecular, and methylation analysis of mesenchymal tumors with <span> <i>NTRK</i> </span> and other kinase gene aberrations Open
Alterations in kinase genes such as NTRK1/2/3 , RET , and BRAF underlie infantile fibrosarcoma (IFS), the emerging entity ‘ NTRK ‐rearranged spindle cell neoplasms’ included in the latest WHO classification, and a growing set of tumors wit…
View article: What is the fuss about FUS fused rhabdomyosarcoma?
What is the fuss about FUS fused rhabdomyosarcoma? Open
Introduction/Objective Rhabdomyosarcoma (RMS) is a rare and aggressive soft tissue sarcoma that primarily affects children and adolescents. It arises from primitive mesenchymal cells committed to skeletal muscle differentiation. Understand…
View article: Acute myeloid leukemia with monocytic differentiation (myeloid sarcoma) masquerading as bone-soft tissue malignancy
Acute myeloid leukemia with monocytic differentiation (myeloid sarcoma) masquerading as bone-soft tissue malignancy Open
Introduction/Objective Myeloid sarcoma is an extramedullary solid neoplasm composed of myeloid precursors with or without maturation. This tumor usually occurs simultaneously or following the onset of acute leukemia. Rarely, it can be the …
View article: Myxofibrosarcoma with false-positive EWSR1 FISH
Myxofibrosarcoma with false-positive EWSR1 FISH Open
Introduction/Objective Myxofibrosarcoma is a common sarcoma in elderly patients. It comprises a spectrum of malignant fibroblastic neoplasms with variable myxoid stroma, pleomorphism, and a distinctive curvilinear vascular pattern. As soft…
View article: Ossifying fasciitis: A rare phenomenon and a mimicker for malignancy
Ossifying fasciitis: A rare phenomenon and a mimicker for malignancy Open
Introduction/Objective Ossifying fasciitis is a relatively rare variant of nodular fasciitis. However, it can mimic malignant lesions, particularly extraosseous osteosarcoma. The purpose of this report is to describe a florid case of ossif…
View article: Giant cell tumor of the clivus misdiagnosed as calcifying fibrous tumor
Giant cell tumor of the clivus misdiagnosed as calcifying fibrous tumor Open
Introduction/Objective Giant cell tumors of bone (GCTs) are generally benign, locally aggressive lesions accounting for approximately 4% of primary bone tumors. GCTs of the skull are rare and constitute <1% of all reported GCTs as they …
View article: Supplementary Figure S5 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Supplementary Figure S5 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma Open
Supplementary Figure S5. T cell changes following αCD40/chemotherapy treatment.
View article: Supplementary Figure S2 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Supplementary Figure S2 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma Open
Supplementary Figure S2. PD-L1 expression on lineage labeled PDA cells in vivo.
View article: Supplementary Methods from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Supplementary Methods from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma Open
Supplementary Methods
View article: Supplementary Figure S1 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Supplementary Figure S1 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma Open
Supplementary Figure S1. PD-L1 expression in human PDA.
View article: Supplementary Figure S7 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Supplementary Figure S7 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma Open
Supplementary Figure S7. Tumor growth curves of individual mice with subcutaneous PDA treated as indicated.
View article: Supplementary Figure S7 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Supplementary Figure S7 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma Open
Supplementary Figure S7. Tumor growth curves of individual mice with subcutaneous PDA treated as indicated.
View article: Supplementary Figure S8 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Supplementary Figure S8 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma Open
Supplementary Figure S8. Non-tumor related events and deaths in tumor bearing C57BL/6 mice after immunotherapy.
View article: Supplemenatry Figure Legends from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Supplemenatry Figure Legends from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma Open
Supplementary Figure Legends
View article: Supplementary Figure S6 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Supplementary Figure S6 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma Open
Supplementary Figure S6. Antitumor effect of αCD40/chemotherapy is macrophage independent.
View article: Supplementary Figure S1 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Supplementary Figure S1 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma Open
Supplementary Figure S1. PD-L1 expression in human PDA.
View article: Data from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Data from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma Open
Disabling the function of immune checkpoint molecules can unlock T-cell immunity against cancer, yet despite remarkable clinical success with monoclonal antibodies (mAb) that block PD-1 or CTLA-4, resistance remains common and essentially …
View article: Supplementary Figure S4 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Supplementary Figure S4 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma Open
Supplementary Figure S4. CD40 expression on APCs in subcutaneous PDA tumors.
View article: Supplementary Figure S3 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Supplementary Figure S3 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma Open
Supplementary Figure S3. CTLA-4 expression on T cell subsets in mice bearing subcutaneous PDA tumors.
View article: Supplementary Methods from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Supplementary Methods from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma Open
Supplementary Methods
View article: Supplementary Figure S6 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Supplementary Figure S6 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma Open
Supplementary Figure S6. Antitumor effect of αCD40/chemotherapy is macrophage independent.
View article: Supplemenatry Figure Legends from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Supplemenatry Figure Legends from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma Open
Supplementary Figure Legends
View article: Data from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Data from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma Open
Disabling the function of immune checkpoint molecules can unlock T-cell immunity against cancer, yet despite remarkable clinical success with monoclonal antibodies (mAb) that block PD-1 or CTLA-4, resistance remains common and essentially …
View article: Supplementary Figure S8 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Supplementary Figure S8 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma Open
Supplementary Figure S8. Non-tumor related events and deaths in tumor bearing C57BL/6 mice after immunotherapy.